Efficacy of low-molecular-weight heparin in acute coronary syndromes.
Wallentin
L
L
Department of Cardiology, Uppsala University Hospital, Sweden.
D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D000925:Anticoagulants / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D055502:Secondary Prevention; D015996:Survival Rate; D000077466:Tirofiban; D016896:Treatment Outcome; D020107:Troponin T / Q000097:blood; D014443:Tyrosine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000925:Anticoagulants; D015415:Biomarkers; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D020107:Troponin T; D014443:Tyrosine; D000077466:Tirofiban